论文部分内容阅读
目的：应用系统评价方法评价立体定向放疗在乳腺癌脑转移瘤中的疗效和安全性。方法检索PubMed、MEDILINE，EMBASE and Cochrane图书馆以及中国生物医学文献数据库等数据库，纳入接受单独立体定向放疗治疗（SRS）对比SRS联合全脑放疗（WBRT）的乳腺癌脑转移的随机对照试验或队列对照研究，检索日期截止至2014年6月。以Cochrane系统评价方法评价纳入研究，提取有效数据后使用RevMan 5.2软件对总生存期、局部控制生存期进行meta分析。结果共纳入2个回顾性队列研究，包括103例患者，meta分析结果显示SRS对比SRS联合WBRT在总生存期(HR=0.85，95%CI[0.56，1.29]，=0.44)，局部控制生存期(HR=1.25，95%CI[0.82，1.90]，=0.30)方面均无明显差别。结论目前证据表明单独SRS对比SRS联合WBRT在乳腺癌脑转移患者中并无明显的生存差别，但在不良反应和局部缓解率方面尚不清楚，需要更多高质量随机对照试验进一步证实。“,”Objective The role of stereotactic radiosurgery (SRS)has became an effective treatment for patients of metastases from breast cancer. Methods Electronic (PubMed,MEDILINE,EMBASE and Cochrane library databases)was conducted throughout June 2014 to identify trails for patients underwent SRS alone or in combination with WBRT for newly diagnosed of brain metastases from breast cancer . The Cochrane Collaboration Review Manage 5.2 statistical software was used for this meta-analysis.Results A total of two retrospective cohort including 103 patients. No significant difference both in overall survival(OS) (HR=0.85,95%CI[0.56,1.29],p=0.44)and local control(LC) time (HR=1.25,95%CI[0.82,1.90],p=0.30)between these two therapies was observed . Conclusion Our finding suggest both SRS and SRS plus WBRT can be selected for newly diagnosed brain metastases patients for breast cancer .But in term of adverse reactions and long-term effects is not clear,the need for more high quality randomized controlled trails confirmed.